Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients

Table 4 Comparison of the drug use pattern of the 127,977 diabetic subjects between 2009 and 2013

Type of therapy	2009 (%)	2013 (%)
Lifestyle modification only	15.7	10.2
Oral anti-diabetic drug only	83.7	86.3
Insulin only	0.2	0.5
Oral anti-diabetic drug + insulin	0.5	3.0
Anti-diabetic drugs
Metformin	71.1	80.4
Sulphonylurea	57.0	60.4
Gliptin	0.0	1.2
Insulin	0.6	3.5
Others	0.1	0.1
Anti-hypertensive drugs^a
None	2.5	3.6
ACEI or ARB	59.4	58.3
β-blocker	39.2	35.5
CCB	73.9	71.0
Diuretic	11.8	10.7
Other anti-hypertensive drugs	15.1	13.8
Lipid lowering drugs
Statin	9.0 (15.8 %)^b	55.0 (56.9 %)^b
Fibrate	4.6	2.5
Aspirin	8.8 (75.8 %)^c	14.0 (75.7 %)^c

Others included Acarbose, Glucagon-like peptide-1 agonist, Meglitinides
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
^aThe denominator was diabetic patients with hypertension (93,234 and 106,361 at 2009 and 2013, respectively)
^bThe bracket shows the proportion of diabetic patients with hyperlipidemia who are put on statin
^cThe bracket shows the proportion of diabetic patients with confirmed CVD who were put on aspirin